Revelation Biosciences REVB
NASDAQ REVB
$0.80 -0.02 (-1.96%)
As of: Oct 1, 2026 · 3:59 PM EDT

Revelation Biosciences (REVB) Preferred Stock Liabilities (2020 - 2021)

Updated

Revelation Biosciences (REVB) recorded Preferred Stock Liabilities of $47.81 million in Q4 2021, down 35.0% from $73.51 million a year earlier and down 35.0% from the prior quarter.

Analysis

Revelation Biosciences (REVB) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends

Starting with Q4 2020, Revelation Biosciences' Preferred Stock Liabilities history includes 5 quarters.

  • Across earlier years, Preferred Stock Liabilities came in at $73.51 million in FY2020.
  • Per Business Quant, the preceding three quarters came in at $73.51 million (Q3 2021), $73.51 million (Q2 2021) and $73.51 million (Q1 2021).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Revelation Biosciences 3.20 Mn -45.82 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 47.81 Mn
Sep 30, 2021 73.51 Mn
Jun 30, 2021 73.51 Mn
Mar 31, 2021 73.51 Mn
Dec 31, 2020 73.51 Mn
API Access

Revelation Biosciences Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=REVB&period=max&api_key=YOUR_API_KEY